Additional file 2: Table S2. of Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer

Additional file 1: Table S1. of A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities

Jean Abraham (3500258)
Louise Hiller (39742)
Leila Dorling (3156525)
Anne-Laure Vallier (3156534)
Janet Dunn (294568)
Sarah Bowden (30796)
Susan Ingle (3156522)
Linda Jones (3500255)
Richard Hardy (3156537)
Christopher Twelves (3440627)
Christopher Poole (3500249)
Paul Pharoah (15105)
Carlos Caldas (1042)
Helena Earl (3500252)

December 2015

Patient characteristics of the 6,248 patients shown by trial. Table S2. National Cancer Institute Co...

Additional file 3: Table S2. of Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Ian Krop (3430586)
Shanu Modi (3568451)
Patricia LoRusso (353749)
Mark Pegram (3568463)
Ellie Guardino (3568457)
Betsy Althaus (3568454)
Dan Lu (135836)
Alexander Strasak (3568460)
Anthony Elias (3449)

March 2016

All-grade AEs (occurring in ≥20 %) or grade ≥3 AEs (occurring in >3 %) of the total patient populati...

Additional file 2: of Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes

Trygve Lofterød (5396501)
Elin Mortensen (5396498)
Hawa Nalwoga (845585)
Tom Wilsgaard (321883)
Hanne Frydenberg (3542120)
Terje Risberg (25586)
Anne Eggen (4100746)
Anne McTiernan (3542132)
Sura Aziz (655431)
Erik Wist (3542126)
Andreas Stensvold (3528713)
Jon Reitan (5396495)
Lars Akslen (4406518)
Inger Thune (315574)

June 2018

Figure S1. Age-adjusted overall survival by breast cancer molecular subtypesa. a Luminal A - ER posi...

Additional file 1: Table S1. of Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer

Yuan Yuan (25702)
Nilesh Vora (4399000)
Can-Lan Sun (4398979)
Daneng Li (4399006)
Enrique Soto-Perez-de-Celis (3531527)
Joanne Mortimer (662501)
The-hang Luu (4398985)
George Somlo (259207)
James Waisman (4398997)
David Smith (37222)
Joseph Chao (4398973)
Vani Katheria (4398994)
Timothy Synold (2408704)
Vivi Tran (4398982)
Shu Mi (4399009)
Abrahm Levi (4398988)
Anait Arsenyan (4398976)
Jennifer Choi (228610)
Laura Zavala (4398991)
Susan Yost (4162609)
Arti Hurria (4399003)

August 2017

Biomarkers measurement in neo-adjuvant-treated vs. adjuvant-treated patients. (DOC 39Â kb

Additional file 2: Table S2A. of Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online

Beate Jahn (170765)
Ursula Rochau (2553013)
Christina Kurzthaler (4516393)
Michael Hubalek (102610)
Rebecca Miksad (4516387)
Gaby Sroczynski (4516390)
Mike Paulden (4516396)
Marvin Bundo (4516399)
David Stenehjem (3455345)
Diana Brixner (3455348)
Murray Krahn (250684)
Uwe Siebert (495818)

October 2017

Sensitivity Analysis of cost effectiveness of chemotherapy in subgroups with a low risk according to...

Additional file 2: Table S2A. of In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis

Michela Bulfoni (3564743)
Lorenzo Gerratana (3564737)
Fabio Del Ben (3564749)
Stefania Marzinotto (3564740)
Marisa Sorrentino (3564746)
Matteo Turetta (3564752)
Giacinto Scoles (659304)
Barbara Toffoletto (3564728)
Miriam Isola (3564731)
Carlo Beltrami (3564734)
Carla Di Loreto (20344)
Antonio Beltrami (3560588)
Fabio Puglisi (20338)
Daniela Cesselli (298854)

March 2016

Presenting enumeration of different CD45neg subgroups, as assessed by FACS, in blood samples obtaine...

Additional file 2: Figure S1. of An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer

Carlo Maley (3309672)
Konrad Koelble (3554393)
Rachael Natrajan (265328)
Athena Aktipis (3554390)
Yinyin Yuan (225403)

September 2015

Supplementary Figures and Tables. This file contains the following figures and tables: Validation of...

Additional file 2: Table S2. of Mammographic density and breast cancer risk: a mediation analysis

Megan Rice (107903)
Kimberly Bertrand (3494756)
Tyler VanderWeele (3548336)
Bernard Rosner (274275)
Xiaomei Liao (3550997)
Hans-Olov Adami (20894)
Rulla Tamimi (89929)

September 2016

Differences in mammographic density measures by breast cancer risk factors in 1727 premenopausal and...

Additional file 1: of Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort

Danja Sarink (5881070)
Helena Schock (3495017)
Theron Johnson (3495092)
Jenny Chang-Claude (23562)
Kim Overvad (115088)
Anja Olsen (93711)
Anne Tjønneland (93710)
Patrick Arveux (91594)
Agnès Fournier (575560)
Marina Kvaskoff (487675)
Heiner Boeing (23585)
Anna Karakatsani (4218592)
Antonia Trichopoulou (115117)
Carlo La Vecchia (360033)
Giovanna Masala (147462)
Claudia Agnoli (115118)
Salvatore Panico (115120)
Rosario Tumino (43188)
Carlotta Sacerdote (140075)
Carla van Gils (3594062)
Petra Peeters (487679)
Elisabete Weiderpass (49201)
Antonio Agudo (115099)
Miguel Rodríguez-Barranco (3816292)
José Huerta (3499376)
Eva Ardanaz (115112)
Leire Gil (5881073)
Kay Kaw (5881076)
Julie Schmidt (3499385)
Laure Dossus (151295)
Mathilde His (485039)
Dagfinn Aune (218439)
Elio Riboli (23604)
Rudolf Kaaks (23598)
Renée Fortner (3495014)

October 2018

Table S1. Circulating concentrations of OPG and risk of death following a breast cancer diagnosis, b...

Additional file 4: Table S2C. of Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online

Beate Jahn (170765)
Ursula Rochau (2553013)
Christina Kurzthaler (4516393)
Michael Hubalek (102610)
Rebecca Miksad (4516387)
Gaby Sroczynski (4516390)
Mike Paulden (4516396)
Marvin Bundo (4516399)
David Stenehjem (3455345)
Diana Brixner (3455348)
Murray Krahn (250684)
Uwe Siebert (495818)

October 2017

Sensitivity Analysis of cost effectiveness of chemotherapy in subgroups with a high risk according t...

Additional file 1: of Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

Nadine Norton (488827)
Nicholas Fox (5392982)
Christie-Ann McCarl (5392979)
Kathleen Tenner (5392988)
Karla Ballman (404207)
Courtney Erskine (5392991)
Brian Necela (3664780)
Donald Northfelt (4609261)
Winston Tan (5392994)
Carmen Calfa (5392985)
Mark Pegram (3568463)
Gerardo Colon-Otero (3472709)
Edith Perez (3439139)
Raphael Clynes (326829)
Keith Knutson (376781)

June 2018

Table S1. Comparison of clinical characteristics of study patients and remaining N9831 cohort. (DOCX...

Additional file 1: Table S1. of The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study

Stefanie de Groot (3585650)
Maaike Vreeswijk (3537473)
Marij Welters (3440804)
Gido Gravesteijn (3585671)
Jan Boei (3585659)
Anouk Jochems (3585656)
Daniel Houtsma (3585665)
Hein Putter (73805)
Jacobus van der Hoeven (3585662)
Johan Nortier (3585653)
Hanno Pijl (123561)
Judith Kroep (3585668)

October 2015

Median of γ-H2AX geomean intensity in CD45 + CD3+ lymphocytes, CD45 + CD14 + CD15- monocytes and CD4...

Additional file 2: Table S1. of Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients

Jithendra Bailur (3437555)
Evelyna Derhovanessian (95110)
Brigitte Gueckel (3437552)
Graham Pawelec (55707)

October 2015

Clinico-pathological characteristics of younger and older patients. (DOCX 15Â kb

Additional file 1: Table S2. of Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients

Jithendra Bailur (3437555)
Evelyna Derhovanessian (95110)
Brigitte Gueckel (3437552)
Graham Pawelec (55707)

October 2015

Kaplan-Meier analysis of clinico-pathological parameters in older patients. (DOCX 17Â kb

Additional file 2: of ER, PgR, Ki67, p27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab

Sasagu Kurozumi (3579641)
Kenichi Inoue (3579644)
Hiroyuki Takei (1839607)
Hiroshi Matsumoto (3020496)
Masafumi Kurosumi (3579638)
Jun Horiguchi (833439)
Izumi Takeyoshi (397385)
Tetsunari Oyama (3579647)

September 2015

Results of the multivariate analysis of clinicopathological factors influencing the prediction of pC...

Additional file 1: Table S1. of A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities

Jean Abraham (3500258)
Louise Hiller (39742)
Leila Dorling (3156525)
Anne-Laure Vallier (3156534)
Janet Dunn (294568)
Sarah Bowden (30796)
Susan Ingle (3156522)
Linda Jones (3500255)
Richard Hardy (3156537)
Christopher Twelves (3440627)
Christopher Poole (3500249)
Paul Pharoah (15105)
Carlos Caldas (1042)
Helena Earl (3500252)

December 2015

Patient characteristics of the 6,248 patients shown by trial. Table S2. National Cancer Institute Co...

Additional file 3: Table S2. of Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Ian Krop (3430586)
Shanu Modi (3568451)
Patricia LoRusso (353749)
Mark Pegram (3568463)
Ellie Guardino (3568457)
Betsy Althaus (3568454)
Dan Lu (135836)
Alexander Strasak (3568460)
Anthony Elias (3449)

March 2016

All-grade AEs (occurring in ≥20 %) or grade ≥3 AEs (occurring in >3 %) of the total patient populati...

Additional file 2: of Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes

Trygve Lofterød (5396501)
Elin Mortensen (5396498)
Hawa Nalwoga (845585)
Tom Wilsgaard (321883)
Hanne Frydenberg (3542120)
Terje Risberg (25586)
Anne Eggen (4100746)
Anne McTiernan (3542132)
Sura Aziz (655431)
Erik Wist (3542126)
Andreas Stensvold (3528713)
Jon Reitan (5396495)
Lars Akslen (4406518)
Inger Thune (315574)

June 2018

Figure S1. Age-adjusted overall survival by breast cancer molecular subtypesa. a Luminal A - ER posi...

Additional file 1: Table S1. of Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer

Yuan Yuan (25702)
Nilesh Vora (4399000)
Can-Lan Sun (4398979)
Daneng Li (4399006)
Enrique Soto-Perez-de-Celis (3531527)
Joanne Mortimer (662501)
The-hang Luu (4398985)
George Somlo (259207)
James Waisman (4398997)
David Smith (37222)
Joseph Chao (4398973)
Vani Katheria (4398994)
Timothy Synold (2408704)
Vivi Tran (4398982)
Shu Mi (4399009)
Abrahm Levi (4398988)
Anait Arsenyan (4398976)
Jennifer Choi (228610)
Laura Zavala (4398991)
Susan Yost (4162609)
Arti Hurria (4399003)

August 2017

Biomarkers measurement in neo-adjuvant-treated vs. adjuvant-treated patients. (DOC 39Â kb

Additional file 2: Table S2A. of Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online

Beate Jahn (170765)
Ursula Rochau (2553013)
Christina Kurzthaler (4516393)
Michael Hubalek (102610)
Rebecca Miksad (4516387)
Gaby Sroczynski (4516390)
Mike Paulden (4516396)
Marvin Bundo (4516399)
David Stenehjem (3455345)
Diana Brixner (3455348)
Murray Krahn (250684)
Uwe Siebert (495818)

October 2017

Sensitivity Analysis of cost effectiveness of chemotherapy in subgroups with a low risk according to...

Additional file 2: Table S2A. of In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis

Michela Bulfoni (3564743)
Lorenzo Gerratana (3564737)
Fabio Del Ben (3564749)
Stefania Marzinotto (3564740)
Marisa Sorrentino (3564746)
Matteo Turetta (3564752)
Giacinto Scoles (659304)
Barbara Toffoletto (3564728)
Miriam Isola (3564731)
Carlo Beltrami (3564734)
Carla Di Loreto (20344)
Antonio Beltrami (3560588)
Fabio Puglisi (20338)
Daniela Cesselli (298854)

March 2016

Presenting enumeration of different CD45neg subgroups, as assessed by FACS, in blood samples obtaine...

Additional file 2: Figure S1. of An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer

Carlo Maley (3309672)
Konrad Koelble (3554393)
Rachael Natrajan (265328)
Athena Aktipis (3554390)
Yinyin Yuan (225403)

September 2015

Supplementary Figures and Tables. This file contains the following figures and tables: Validation of...

Additional file 2: Table S2. of Mammographic density and breast cancer risk: a mediation analysis

Megan Rice (107903)
Kimberly Bertrand (3494756)
Tyler VanderWeele (3548336)
Bernard Rosner (274275)
Xiaomei Liao (3550997)
Hans-Olov Adami (20894)
Rulla Tamimi (89929)

September 2016

Differences in mammographic density measures by breast cancer risk factors in 1727 premenopausal and...

Additional file 1: of Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort

Danja Sarink (5881070)
Helena Schock (3495017)
Theron Johnson (3495092)
Jenny Chang-Claude (23562)
Kim Overvad (115088)
Anja Olsen (93711)
Anne Tjønneland (93710)
Patrick Arveux (91594)
Agnès Fournier (575560)
Marina Kvaskoff (487675)
Heiner Boeing (23585)
Anna Karakatsani (4218592)
Antonia Trichopoulou (115117)
Carlo La Vecchia (360033)
Giovanna Masala (147462)
Claudia Agnoli (115118)
Salvatore Panico (115120)
Rosario Tumino (43188)
Carlotta Sacerdote (140075)
Carla van Gils (3594062)
Petra Peeters (487679)
Elisabete Weiderpass (49201)
Antonio Agudo (115099)
Miguel Rodríguez-Barranco (3816292)
José Huerta (3499376)
Eva Ardanaz (115112)
Leire Gil (5881073)
Kay Kaw (5881076)
Julie Schmidt (3499385)
Laure Dossus (151295)
Mathilde His (485039)
Dagfinn Aune (218439)
Elio Riboli (23604)
Rudolf Kaaks (23598)
Renée Fortner (3495014)

October 2018

Table S1. Circulating concentrations of OPG and risk of death following a breast cancer diagnosis, b...

Additional file 4: Table S2C. of Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online

Beate Jahn (170765)
Ursula Rochau (2553013)
Christina Kurzthaler (4516393)
Michael Hubalek (102610)
Rebecca Miksad (4516387)
Gaby Sroczynski (4516390)
Mike Paulden (4516396)
Marvin Bundo (4516399)
David Stenehjem (3455345)
Diana Brixner (3455348)
Murray Krahn (250684)
Uwe Siebert (495818)

October 2017

Sensitivity Analysis of cost effectiveness of chemotherapy in subgroups with a high risk according t...

Additional file 1: of Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

Nadine Norton (488827)
Nicholas Fox (5392982)
Christie-Ann McCarl (5392979)
Kathleen Tenner (5392988)
Karla Ballman (404207)
Courtney Erskine (5392991)
Brian Necela (3664780)
Donald Northfelt (4609261)
Winston Tan (5392994)
Carmen Calfa (5392985)
Mark Pegram (3568463)
Gerardo Colon-Otero (3472709)
Edith Perez (3439139)
Raphael Clynes (326829)
Keith Knutson (376781)

June 2018

Table S1. Comparison of clinical characteristics of study patients and remaining N9831 cohort. (DOCX...

Additional file 1: Table S1. of The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study

Stefanie de Groot (3585650)
Maaike Vreeswijk (3537473)
Marij Welters (3440804)
Gido Gravesteijn (3585671)
Jan Boei (3585659)
Anouk Jochems (3585656)
Daniel Houtsma (3585665)
Hein Putter (73805)
Jacobus van der Hoeven (3585662)
Johan Nortier (3585653)
Hanno Pijl (123561)
Judith Kroep (3585668)

October 2015

Median of γ-H2AX geomean intensity in CD45 + CD3+ lymphocytes, CD45 + CD14 + CD15- monocytes and CD4...

Additional file 2: Table S1. of Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients

Jithendra Bailur (3437555)
Evelyna Derhovanessian (95110)
Brigitte Gueckel (3437552)
Graham Pawelec (55707)

October 2015

Clinico-pathological characteristics of younger and older patients. (DOCX 15Â kb

Additional file 1: Table S2. of Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients

Jithendra Bailur (3437555)
Evelyna Derhovanessian (95110)
Brigitte Gueckel (3437552)
Graham Pawelec (55707)

October 2015

Kaplan-Meier analysis of clinico-pathological parameters in older patients. (DOCX 17Â kb

Additional file 2: of ER, PgR, Ki67, p27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab

Sasagu Kurozumi (3579641)
Kenichi Inoue (3579644)
Hiroyuki Takei (1839607)
Hiroshi Matsumoto (3020496)
Masafumi Kurosumi (3579638)
Jun Horiguchi (833439)
Izumi Takeyoshi (397385)
Tetsunari Oyama (3579647)

September 2015

Results of the multivariate analysis of clinicopathological factors influencing the prediction of pC...

Additional file 1: Table S1. of A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities

Jean Abraham (3500258)
Louise Hiller (39742)
Leila Dorling (3156525)
Anne-Laure Vallier (3156534)
Janet Dunn (294568)
Sarah Bowden (30796)
Susan Ingle (3156522)
Linda Jones (3500255)
Richard Hardy (3156537)
Christopher Twelves (3440627)
Christopher Poole (3500249)
Paul Pharoah (15105)
Carlos Caldas (1042)
Helena Earl (3500252)

December 2015

Patient characteristics of the 6,248 patients shown by trial. Table S2. National Cancer Institute Co...

Additional file 3: Table S2. of Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Ian Krop (3430586)
Shanu Modi (3568451)
Patricia LoRusso (353749)
Mark Pegram (3568463)
Ellie Guardino (3568457)
Betsy Althaus (3568454)
Dan Lu (135836)
Alexander Strasak (3568460)
Anthony Elias (3449)

March 2016

All-grade AEs (occurring in ≥20 %) or grade ≥3 AEs (occurring in >3 %) of the total patient populati...

Additional file 2: of Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes

Trygve Lofterød (5396501)
Elin Mortensen (5396498)
Hawa Nalwoga (845585)
Tom Wilsgaard (321883)
Hanne Frydenberg (3542120)
Terje Risberg (25586)
Anne Eggen (4100746)
Anne McTiernan (3542132)
Sura Aziz (655431)
Erik Wist (3542126)
Andreas Stensvold (3528713)
Jon Reitan (5396495)
Lars Akslen (4406518)
Inger Thune (315574)

June 2018

Figure S1. Age-adjusted overall survival by breast cancer molecular subtypesa. a Luminal A - ER posi...

Additional file 2: Table S2. of Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer

Abstract

Extracted data

Additional file 2: Table S2. of Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer

Abstract

Extracted data

Related items

Related items